angiogenesis inhibitors

systematic review meta-analysis network meta-analysis

Select advanced breast cancer (metastatic)lung cancer (metastatic)renal-cell carcinoma (advanced) All type of patientuncoded clinical condition ***       anti angiogenesis antibodybevacizumabcombination with CTcombination with CT (without taxanes)combination with ETcombination with taxanes aflibercept ceritinibmotesanib vandetanib bevacizumabdocetaxelpazopanibsorafenibsunitinib vs CT alonevs endocrine therapy alonevs no bevacizumabvs taxanes alone       1st line2nd lineHER-2 negative

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	progression or death (progression free survival PFS) (22)death (overall survival) (20)objective response (ORR) (17)heart failure (grade 3) (10)treatment-related deaths (10)permanent discontinuation (10)hypertension (grade 3) (10)gastrointestinal perforation (grade 3) (8)bleeding (grade 3) (8)serious adverse events (6)arterial/venous thromboembolism (grade 3) (3)cardiomyopathy (grade 3) (2) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	progression or death (progression free survival PFS)	death (overall survival)
advanced breast cancer (metastatic)
bevacizumab
RIBBON-I (Robert) on top capecitabine, 2009	bevacizumab + capecitabine	capecitabine		1st line	Low risk of bias	suggesting
AVF2119g (Miller) cape, 2005	bevacizumab + capecitabine	capecitabine		2nd line	Risk of bias	suggesting
RIBBON-2 (Brufsky), 2009	bevacizumav + CT	CT alone		2nd line		suggesting
AVADO (Miles) 15mg , 2009	bevacizumab + docetaxel	docetaxel		1st line HER-2 negative		suggesting
AVADO (Miles) 7.5mg, 2010	bevacizumab + docetaxel	docetaxel		1st line HER-2 negative	Low risk of bias	negative
Burstein, 2005	bevacizumab + methotrexate	methotrexate				negative
Martin bevacizumab, 2011	bevacizumab + paclitaxel	paclitaxel		1st line HER-2 negative	Risk of bias	negative
RIBBON-I (Robert) on top Tax or anthra, 2009	bevacizumab + taxanes	taxanes		1st line		suggesting
E2100 (Miller), 2007      NCT	bevacizumab + taxanes	taxanes		1st line	Risk of bias	suggesting
ceritinib
Hyams      NCT	cediranib + fulvestrant	fulvestrant				-
motesanib
Martin (motesanib), 2011      NCT	motesanib + paclitaxel	paclitaxel		1st line HER-2 negative	Low risk of bias	-
sorafenib
Schwartzberg, 2013      NCT	sorafenib + gemcitabine or capecitabine	gemcitabine or capecitabine alone		2nd line HER-2 negative	Exploratory	suggesting
Gradishar, 2013	sorafenib + paclitaxel	paclitaxel alone		1st line HER-2 negative	Low risk of bias	negative
lung cancer (metastatic)
aflibercept
Ramlau, 2012	Aflibercept and Docetaxel	Docetaxel			Low risk of bias	-
bevacizumab
Reck, 2010	bevacizumab					-
Herbst, 2011	bevacizumab + erlotinib	erlotinib alone				-
Sandler, 2006	bevacizumab	platinum based CT				-
Johnson, 2004	bevacizumab	platinum based CT				-
Nishio, 2009	bevacizumab	platinum based CT				-
Herbst, 2007	bevacizumab	platinum based CT				-
ceritinib
Laurie, 2014	cediranib	carboplatin and paclitaxel				-
Goss, 2010	cediranib	carboplatin and paclitaxel				-
Dy, 2013	cediranib	gemcitabine and carboplatin				-
docetaxel
REVEL, 2014      NCT	ramucirumab + docetaxel	docetaxel alone			Low risk of bias	-
motesanib
Scagliottib MONET1, 2012	motesanib plus carboplatin/paclitaxel					-
pazopanib
Scagliotti, 2013	pazopanib	pemetrexed				-
sorafenib
Wakelee, 2012	sorafenib					-
Paz-Ares, 2012	sorafenib					-
Spigel, 2011	sorafenib and erlotinib	erlotinib				-
Scagliotti, 2010	sorafenib	placebo				-
sunitinib
Groen, 2013	sunitinib	erlotinib			Low risk of bias	-
Scagliottia, 2012	Sunitinib plus erlotinib	erlotinib				-
Heist CALGB 30704 (Alliance): , 2014	sunitinib	pemetrexed				-
vandetanib
Aisner, 2013	vandetanib					-
Ahn, 2013	vandetanib maintenance					-
de Boer, 2011	Vandetanib plus pemetrexed					-
Natale, 2009	Vandetanib versus gefitinib				Low risk of bias	-
Natale, 2011	Vandetanib	gefitinib			Low risk of bias	-
Lee ZEPHYR, 2012	Vandetanib	placebo				-
Heymach, 2007	vandetanib plus docetaxel	placebo plus docetaxel				-
renal-cell carcinoma (advanced)
bevacizumab
CALGB 90206, 2010	bevacizumab plus interferon alfa	interferon alpha				suggesting
AVOREN, 2007	bevacizumab plus interferon alfa	interferon alpha				suggesting
Yang, 2003	bevacizumab	placebo			Exploratory	-